Iovance Biotherapeutics (NASDAQ:IOVA) is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.
Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes. This personalized approach aims to deliver a potent and durable anti‐tumor response, leveraging automated manufacturing processes developed in partnership with contract development and manufacturing organizations. The company’s clinical programs are supported by a comprehensive network of manufacturing sites and clinical trial locations across the United States and Europe.
Founded in 2007 as Lion Biotechnologies and rebranded to Iovance Biotherapeutics in 2017, the company is headquartered in San Carlos, California. Since its inception, Iovance has advanced its cell therapy technologies from early research through pivotal registration trials, collaborating with leading academic centers and regulatory agencies to refine its manufacturing and clinical processes. The company’s international footprint includes trial sites in North America, Europe and Latin America.
Iovance is led by a management team with extensive experience in oncology drug development and cell therapy commercialization. Maria Fardis, President and Chief Executive Officer, oversees strategic direction and operational execution, supported by senior leaders in clinical development, manufacturing and regulatory affairs. Together, the team seeks to bring transformational immunotherapies to patients with high‐unmet‐need solid tumors.
